Related Experiment Video
Updated: Jan 10, 2026
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Preclinical assessment of genetically modified exosomes for colorectal cancer immunotherapy
Thuc Oanh Hoang1, Lei Zhang1, Sunny H Kim1
1Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, United States.
Abstract:
Colorectal cancer (CRC) claims nearly one million lives every year worldwide. Current treatments for CRC suffer from limited efficacy and developed resistance. Exosomes are cell-derived membranous vesicles, characterized by unique properties for drug discovery. We previously designed genetically engineered multifunctional immune-modulating exosomes (GEMINI-Exos) with surface-displayed antibodies against T-cell CD3 and cancer-associated epidermal growth factor receptor (EGFR) antigens as well as programmed death 1 receptors and OX40 ligands. Here, GEMINI-Exos were evaluated in cellular and animal models of CRC. By recruiting and activating cytotoxic T cells toward attacking EGFR-positive CRC cells and subsequently engaging with distinct checkpoint pathways, GEMINI-Exos elicit robust cellular immunity to CRC tumors in vitro and in vivo. This work presents GEMINI-Exos as an immunotherapeutic candidate with promising preclinical activity for CRC.
Insights
Genetically engineered exosomes (GEMINI-Exos) show promise in treating colorectal cancer (CRC). These engineered exosomes activate immune cells to target and destroy CRC tumors, offering a potential new immunotherapy.
Area of Science:
- Immunology
- Oncology
- Nanotechnology
Background:
- Colorectal cancer (CRC) is a leading cause of cancer death globally.
- Current CRC treatments face challenges with efficacy and drug resistance.
- Exosomes offer unique potential for drug delivery and cancer therapy.
Purpose of the Study:
- To evaluate genetically engineered multifunctional immune-modulating exosomes (GEMINI-Exos) in preclinical models of colorectal cancer.
- To assess the ability of GEMINI-Exos to recruit and activate cytotoxic T cells against EGFR-positive CRC cells.
- To investigate the engagement of distinct checkpoint pathways by GEMINI-Exos for enhanced anti-tumor immunity.
Main Methods:
- Design of GEMINI-Exos with surface antibodies targeting CD3, EGFR, PD-1, and OX40 ligand.
- In vitro testing of GEMINI-Exos in cellular models of CRC.
- In vivo evaluation of GEMINI-Exos in animal models of CRC.
Main Results:
- GEMINI-Exos effectively recruit and activate cytotoxic T cells to attack EGFR-positive CRC cells.
- GEMINI-Exos demonstrate robust induction of cellular immunity against CRC tumors.
- Preclinical studies show significant anti-tumor activity of GEMINI-Exos in vitro and in vivo.
Conclusions:
- GEMINI-Exos represent a novel immunotherapeutic strategy for colorectal cancer.
- The engineered exosomes show promising preclinical efficacy in CRC models.
- GEMINI-Exos hold potential as a future treatment for colorectal cancer.
